Investors

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, ADX-102, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.

Press Releases

Feb 21, 2018
Jan 30, 2018
Nov 29, 2017
Nov 9, 2017
Nov 7, 2017

Corporate Presentation


Events


Scientific Posters & Presentations